Bioprinting Decellularized Breast Tissue for the Development of Three-Dimensional Breast Cancer Models.
3D in vitro cancer model
bioprinting
breast tissue
decellularization
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
06 Jul 2022
06 Jul 2022
Historique:
pubmed:
24
6
2022
medline:
8
7
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
The tumor extracellular matrix (ECM) plays a vital role in tumor progression and drug resistance. Previous studies have shown that breast tissue-derived matrices could be an important biomaterial to recreate the complexity of the tumor ECM. We have developed a method for decellularizing and delipidating a porcine breast tissue (TDM) compatible with hydrogel formation. The addition of gelatin methacrylamide and alginate allows this TDM to be bioprinted by itself with good printability, shape fidelity, and cytocompatibility. Furthermore, this bioink has been tuned to more closely recreate the breast tumor by incorporating collagen type I (Col1). Breast cancer cells (BCCs) proliferate in both TDM bioinks forming cell clusters and spheroids. The addition of Col1 improves the printability of the bioink as well as increases BCC proliferation and reduces doxorubicin sensitivity due to a downregulation of HSP90. TDM bioinks also allow a precise three-dimensional printing of scaffolds containing BCCs and stromal cells and could be used to fabricate artificial tumors. Taken together, we have proven that these novel bioinks are good candidates for biofabricating breast cancer models.
Identifiants
pubmed: 35735173
doi: 10.1021/acsami.2c00920
pmc: PMC9264314
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29467-29482Références
Trends Biotechnol. 2022 Apr;40(4):432-447
pubmed: 34556340
ACS Biomater Sci Eng. 2021 Nov 8;7(11):5288-5300
pubmed: 34661396
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Br J Cancer. 2008 May 6;98(9):1515-24
pubmed: 18382425
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
Int J Oncol. 2012 Jul;41(1):267-75
pubmed: 22469755
ACS Appl Mater Interfaces. 2016 Nov 09;8(44):30017-30026
pubmed: 27766838
Acta Biomater. 2010 Dec;6(12):4657-65
pubmed: 20620246
ACS Appl Mater Interfaces. 2016 Aug 31;8(34):22005-17
pubmed: 27494432
J Cell Physiol. 2019 Jun;234(6):9447-9456
pubmed: 30478896
Nat Cell Biol. 2015 May;17(5):678-88
pubmed: 25893917
Nat Protoc. 2006;1(6):2753-8
pubmed: 17406532
ACS Appl Mater Interfaces. 2018 Feb 28;10(8):6849-6857
pubmed: 29405059
Biomaterials. 2020 Mar;235:119705
pubmed: 31978840
Biomaterials. 2014 Jun;35(18):4940-9
pubmed: 24661550
Mol Pharm. 2008 Sep-Oct;5(5):849-62
pubmed: 18680382
Front Cell Dev Biol. 2019 Jul 05;7:86
pubmed: 31334229
Adv Sci (Weinh). 2019 Jun 11;6(15):1900867
pubmed: 31406678
Sci Rep. 2018 Mar 28;8(1):5333
pubmed: 29593247
Stem Cells Dev. 2008 Oct;17(5):993-1003
pubmed: 18537463
Mater Sci Eng C Mater Biol Appl. 2018 Feb 1;83:195-201
pubmed: 29208279
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Acta Biomater. 2015 Feb;13:101-10
pubmed: 25463489
Front Bioeng Biotechnol. 2020 Dec 22;8:611796
pubmed: 33425875
F1000Res. 2018 Mar 5;7:274
pubmed: 29983921
Chem Rev. 2020 Oct 14;120(19):11028-11055
pubmed: 32856892
Life Sci. 2010 Nov 20;87(19-22):587-95
pubmed: 20875431
Int J Mol Sci. 2018 Sep 25;19(10):
pubmed: 30257480
Matrix Biol. 2020 Jan;85-86:80-93
pubmed: 31323325
Materials (Basel). 2019 Oct 12;12(20):
pubmed: 31614735
Acta Biomater. 2019 Sep 1;95:201-213
pubmed: 31233891
NPJ Precis Oncol. 2020 Jul 27;4:18
pubmed: 32793806
Breast Cancer Res. 2020 Jul 31;22(1):82
pubmed: 32736579
Materials (Basel). 2018 Mar 20;11(3):
pubmed: 29558424
Cell Rep. 2019 Jan 15;26(3):608-623.e6
pubmed: 30650355
Trends Biotechnol. 2020 Dec;38(12):1397-1414
pubmed: 32416940
Acta Biomater. 2015 Oct;25:24-34
pubmed: 26210285
Curr Opin Oncol. 2014 Nov;26(6):551-5
pubmed: 25279962
Adv Cancer Res. 2015;125:139-70
pubmed: 25640269
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2477-92
pubmed: 25517985
Discov Med. 2018 May;25(139):211-223
pubmed: 29906404
Oncol Rep. 2010 Nov;24(5):1121-31
pubmed: 20878101
Acta Biomater. 2017 Feb;49:1-15
pubmed: 27915024
Oncotarget. 2017 Jul 8;9(37):24653-24671
pubmed: 29872495
Breast Cancer Res. 2012 Apr 17;14(2):R62
pubmed: 22510516
Sci Adv. 2017 Sep 13;3(9):e1700764
pubmed: 28924608
J Control Release. 2021 May 10;333:91-106
pubmed: 33774120
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Adv Sci (Weinh). 2021 Jan 04;8(4):2003129
pubmed: 33643799
Polymers (Basel). 2016 Jul 26;8(8):
pubmed: 30974547
N Am J Med Sci. 2011 May;3(5):227-33
pubmed: 22558599
Adv Drug Deliv Rev. 2016 Feb 1;97:41-55
pubmed: 26743193
PLoS One. 2015 Jul 06;10(7):e0125766
pubmed: 26147197
Int J Cancer. 2003 Jul 1;105(4):568-73
pubmed: 12712452
Biofabrication. 2016 Oct 07;8(4):045002
pubmed: 27716628
Cancer Res. 2001 Feb 15;61(4):1320-6
pubmed: 11245428
Drug Resist Updat. 2012 Feb-Apr;15(1-2):39-49
pubmed: 22335920
ACS Biomater Sci Eng. 2018 Dec 10;4(12):4401-4411
pubmed: 33418833
Eur J Cancer. 2019 Nov;121:154-171
pubmed: 31581056
Biomaterials. 2011 Apr;32(12):3233-43
pubmed: 21296410
Breast Cancer Res. 2017 Jan 19;19(1):9
pubmed: 28103936
Ann Biomed Eng. 2015 Mar;43(3):568-76
pubmed: 25344351
Acta Biomater. 2020 Apr 1;106:1-21
pubmed: 32045679
Int J Exp Pathol. 2018 Apr;99(2):58-76
pubmed: 29671911
Cancer Treat Rev. 2013 Jun;39(4):375-87
pubmed: 23199899
Histol Histopathol. 2008 Aug;23(8):965-72
pubmed: 18498071
Nat Commun. 2014 Jun 02;5:3935
pubmed: 24887553
Cancer Cell. 2012 Feb 14;21(2):227-39
pubmed: 22340595
Acta Biomater. 2015 Sep;23 Suppl:S17-26
pubmed: 26235342